Sanofi posts 1st-qtr profits downturn but beats estimates

30 April 2015

French pharma major Sanofi (Euronext: SAN) revealed this morning that first-quarter 2015 group sales increased 2.4% at constant rates, or 12.3% on a reported basis, to 8.81 billion euros ($9.82 billion, but net profit fell 6% to 1.02 billion euros. Sanofi’s shares dipped 1% to 90.63 euros in mid-morning trading.

Business net income, ie, adjusted income excluding the impact of acquisitions and divestments, increased 12% to 1.73 billion euros, helped by a weaker euro and its Genzyme biotech business, beating analysts’ expected business net income of 1.58 billion euros, according to a poll by The Wall Street Journal.

Full year guidance

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical